| Species |
Human |
| Protein Construction |
CD6 (His18-Leu402)
Accession # NP_006716.3 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CD6, His, Human at 1μg/ml (100μl/well) on the plate can bind Human ALCAM, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
42.14 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 70-90 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS，(pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized CD6, His, Human, His Tag at 1 μg/ml (100 μg/well) on the plate. Dose response curve for Human ALCAM, hFc Tag with the EC50 of 8.1 ng/ml determined by ELISA.
The purity of CD6, His, Human is greater than 95% as determined by SEC-HPLC.
CD6, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
| Target Background |
The cell surface glycoprotein CD6 is expressed on leukocytes and mediates T cell trafficking across endothelial cell barriers. CD6 is a lymphocyte surface co-receptor physically associated with the T-cell receptor (TCR)/CD3 complex at the center of the immunological synapse. |
| Synonyms |
CD6; TP120; T12 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
